Similarly, high MTBP protein expression was associated with decreased patient survival (p = 0.024) and with resistance to sorafenib therapy (p = 0.0025) in a panel of 120 and 52 HCC patients, respectively [112,114]. The gene discussed is MTBP; the disease is hepatocellular carcinoma.